尿激酶和尿激酶联合低分子肝素钙治疗急性心肌梗死的临床对比分析-论文.pdf

《尿激酶和尿激酶联合低分子肝素钙治疗急性心肌梗死的临床对比分析-论文.pdf》由会员上传分享，免费在线阅读，更多相关内容在行业资料-天天文库。

1、论著China&ForeignMedic—alTreatment口——誓固■譬■■尿激酶和尿激酶联合低分子肝素钙治疗急性心肌梗死的临床对比分析张英武汉市江汉大学附属医院第六医院西药剂科，湖北武汉430015【摘要】目的探讨分析尿激酶和尿激酶联合低分子肝素治疗急性心肌梗死的临床效果。方法选取该院2011年3月一2012年9月收治的心肌梗死患者80例，随机分为治疗组和对照组，每组40例。对照组在常规治疗的基础上给予尿激酶治疗，治疗组在对照组的基础上加用低分子肝素，观察两组患者的临床治疗效果。结果对照组血管再通率为70％，对照组血管再通率为95％，治疗组的血管再通率显著优于对照组，差异有统计学意义

2、

3、iumintheTreatmentofAcuteMyocardialInfarctionZHANGYingDepartmentofPh~nacy，TheSixthAEdiatedHospitalofJianghanUniversity，Wuhan，HubeiProvince430015，China[Abstract]ObjectiveTocomparetheclinicaleficacyofurokinasealonewithurokinasecombinedwithlowmolecularweightheparincalciuminthetreatmentofacutemyocardial

4、infarction．Methods80casesofpatientswithmyocardialinfarctionadmittedinourhospitalfromMarch．2011toSeptember,2012wereselectedanddi~dedintotreatmentgroup(40patients)andcontrolgroup(40patients)．Onthebasisofconventionaltreatment，thepatientsinthecontrolgroupweretreatedwithurokinaseandthepatientsinthetreat

5、mentgroupweretreatedwithurokinasecombinedwithlowmolecularweightheparincalcium．Thetherapeuticefectofthetwogroupswereobserved．ResultsThetreatmentgroup’Svascularrecanalizationratewas95％，muchhigherthanthecontrolgroup’S70％，thediferencewasstatisticallysignificant(P<0．05)．Thetreatmentgroup’Slong-termbleed

6、ingratewas10％．muchlowerthanthecontrolgroup’S37-5％．thediferenceWasstatisticallysignificant．05)．CondusionUrokinasecombinedwithlowmolecularweightheparincalciumisquiteefectiveinthetreatmentofacutemyocardialinfarction，anditCansignificantlyincreasethesuccessrateofthrombolysis，reducelong-termbleedingrate，

7、whichisworthyofclinicalapplication．[Keywords]Uroldnase；Lowmolecularweightheparincalcium；Acutemyocardialinfarction随着我国经济迅速发展，人们生活压力普遍偏大，加上3268岁，平均(43．44-10．4)岁，合并有高血压的有18例，合人口老龄化的加重，急性心肌梗死发病率逐年增高，已成为并有糖尿病的有7